What type of study is this?

This is a RCT study (also classified as: Observational).

Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals microbiome influences treatment outcomes in cancer, suggesting vital predictors for immunotherapy success.

Microbiome diversity correlates with improved progression-free survival in cancer patients receiving immunotherapy.
Viral status, especially from hepatitis B and human papillomavirus, significantly predicts treatment response rates.
Bacterial enrichment is linked to enhanced survival rates in patients with hepatobiliary and lung cancers.
Multi-microbiome models outperform traditional predictors in forecasting outcomes of immune checkpoint inhibitors.

Huang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals microbiome influences treatment outcomes in cancer, suggesting vital predictors for immunotherapy success.

Microbiome diversity correlates with improved progression-free survival in cancer patients receiving immunotherapy.
Viral status, especially from hepatitis B and human papillomavirus, significantly predicts treatment response rates.
Bacterial enrichment is linked to enhanced survival rates in patients with hepatobiliary and lung cancers.
Multi-microbiome models outperform traditional predictors in forecasting outcomes of immune checkpoint inhibitors.

Huang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark